Role of defensins in the pathogenesis of chronic lung allograft rejection by Tiriveedhi, Venkataswarup et al.
Tennessee State University 
Digital Scholarship @ Tennessee State University 
Biology Faculty Research Department of Biological Sciences 
12-28-2013 
Role of defensins in the pathogenesis of chronic lung allograft 
rejection 
Venkataswarup Tiriveedhi 
Tennessee State University 
Babak Banan 
Washington University School of Medicine 
Saini Deepti 
Washington University School of Medicine 
Angaswamy Nataraju 
Washington University School of Medicine 
Ramsey Hachem 
Washington University School of Medicine 
See next page for additional authors 
Follow this and additional works at: https://digitalscholarship.tnstate.edu/biology_fac 
 Part of the Respiratory System Commons, and the Tissues Commons 
Recommended Citation 
Venkataswarup Tiriveedhi, Babak Banan, Saini Deepti, Angaswamy Nataraju, Ramsey Hachem, Elbert 
Trulock, Patterson G. Alexander, Thalachallour Mohanakumar, "Role of defensins in the pathogenesis of 
chronic lung allograft rejection", Human Immunology, Volume 75, Issue 4, 2014, Pages 370-377, ISSN 
0198-8859, https://doi.org/10.1016/j.humimm.2013.12.014. 
This Article is brought to you for free and open access by the Department of Biological Sciences at Digital 
Scholarship @ Tennessee State University. It has been accepted for inclusion in Biology Faculty Research by an 
authorized administrator of Digital Scholarship @ Tennessee State University. For more information, please contact 
XGE@Tnstate.edu. 
Authors 
Venkataswarup Tiriveedhi, Babak Banan, Saini Deepti, Angaswamy Nataraju, Ramsey Hachem, Elbert 
Trulock, Patterson G. Alexander, and Thalachallour Mohanakumar 
This article is available at Digital Scholarship @ Tennessee State University: https://digitalscholarship.tnstate.edu/
biology_fac/83 
Role of defensins in the pathogenesis of chronic lung allograft
rejection
Venkataswarup Tiriveedhi1,5,*, Babak Banan1,*, Saini Deepti1, Angaswamy Nataraju1,
Ramsey Hachem3, Elbert Trulock3, Patterson G. Alexander4, and Mohanakumar
Thalachallour1,2
1Department of Surgery, Washington University School of Medicine, Saint Louis, Missouri- 63110
2Department of Pathology and Immunology, Washington University School of Medicine, Saint
Louis, Missouri- 63110
3Department of Internal Medicine, Washington University School of Medicine, Saint Louis,
Missouri- 63110
4Department of Cardiothoracic Surgery, Washington University School of Medicine, Saint Louis,
Missouri- 63110
5Department of Biological Sciences, Tennessee State University; Nashville, TN-37209.
Abstract
Chronic rejection predominantly manifested as bronchiolitis obliterans syndrome (BOS), still
remains a major problem affecting long-term outcomes in human lung transplantation (LTx).
Donor specific antibodies (DSA) and infiltration of neutrophils in the graft have been associated
with the development of BOS. This study determines the role of defensins, produced by
neutrophils, and its interaction with α-1-antitrypsin (AAT) towards induction of airway
inflammation and fibrosis which are characteristic hallmarks of BOS. Bronchoalveolar lavage
(BAL) and serum from LTx recipients, BOS+ (n=28), BOS-(n=26) and normal healthy controls
(n=24) were analyzed. Our results show that BOS+ LTx recipients had higher α-defensins
(HNP1-3) and β-defensin2 HBD2 concentration in BAL and serum compared to BOS-DSA-
recipients and normal controls (p=0.03). BOS+ patients had significantly lower serum AAT along
with higher circulating concentration of HNP-AAT complexes in BAL (p=0.05). Stimulation of
primary small airway epithelial cells (SAECs) with HNPs induced expression of HBD2, adhesion
molecules (ICAM and VCAM), cytokines (IL-6, IL-1β, IL-13, IL-8 and MCP-1) and growth-
factor (VEGF and EGF). In contrast, anti-inflammatory cytokine, IL-10 expression decreased 2
fold (p=0.002). HNPs mediated SAEC activation was completely abrogated by AAT. In
conclusion, our results demonstrates that neutrophil secretory product, α-defensins, stimulate β-
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defensin production by SAECs causing upregulation of pro-inflammatory and pro-fibrotic
signaling molecules. Hence, chronic stimulation of airway epithelial cells by defensins can lead to
inflammation and fibrosis the central events in the development of BOS following LTx.
Keywords
HNP- Human Neutrophil Peptide; BOS-Bronchiolitis Obliterans Syndrome; BAL-
Bronchoalveolar Lavage; HBD2-Human Beta Defensin 2; SAEC- Small Airway Epithelial Cells
1. Introduction
Long-term survival following human lung transplantation (LTx) is hampered due to chronic
allograft rejection, clinically manifested as bronchiolitis obliterans syndrome (BOS)
affecting 50–60° of LTx recipients in 5 years [1, 2]. Initial Inflammatory damage such as
neutrophilia and their associated products, IL-8, and myeloperoxidase, leading to
development of fibrosis around small airways is considered the central pathogenesis of BOS
[3, 4]. Although multiple risk factors have been proposed to play major role in the
development of BOS, recent evidence strongly suggests towards a role of allo- and auto-
immune mediated injury as a significant risk factor [5]. In addition recent studies from our
laboratory using a murine model of obliterative airway disease which is considered to have
similarity to BOS, we have demonstrated that neutrophil infiltration following
administration of antibodies specific to MHC and damage is an important initiating factor
towards development of OAD [6]. Bronchoalveolar lavage (BAL) from LTx recipients have
shown to contain increased neutrophils and their inflammatory products including human
neutrophil peptides (HNP1, 2, 3/α–defensins)[7]. These peptides have been reported to exert
chemotactic and cytotoxic activity in BAL and participate in host defense and inflammation
[1, 7]. Activation of neutrophils leads to release of HNP1-3. Although normal plasma shows
low levels of HNPs, in many inflammatory conditions including sepsis the levels of HNP is
elevated > 170μg/ml [8]. Human β-defensins, produced by epithelial cells, also act as
chemokines for activation of immature dendritic cells and T cells and provide a link between
innate and adaptive immunity[9].
Alpha-1-antitrypsin (AAT), a serine protease inhibitor (serpin), has been shown to form
complexes with HNP1-3 and inhibit its inflammatory activity [10]. One of its functions is to
inactivate neutrophil elastase and other neutrophil-derived proteinases, and prevent the
destruction of pulmonary extracellular matrix. Deficiency of AAT can cause emphysema
due to degradation of interstitial elastin [11, 12]. Complex interactions between AAT and
defensin are thought to have a role in regulating inflammation [13]. Hence, we propose that
an increase in the HNP levels may result in low levels of AAT and this reduction in AAT
with concomitant increase in defensins may favor non-alloimmune airway injury with
neutrophil degranulation and reduced antiprotease defense.
In this study, we demonstrate that α-defensins stimulate airway epithelial cells to produce β-
defensin2 and increased expression of inflammatory cytokines (IL-13, IL-8, IL-1β, IL-6 and
MCP-1) that augment the adaptive immune responses. This leads to increased expression of
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pro-fibrotic growth factors including VEGF and EGF, which can lead to fibrosis, the
hallmark of BOS following human LTx.
2. Materials and Methods
2.1 Human subjects
LTx recipients at Washington University Medical Center/Barnes-Jewish Hospital
(2000-2007) were enrolled after informed consent according to protocol approved by
institutional review board. BOS+ (n = 28) and BOS− (n = 26) patients were matched for
gender and time following LTx (Table 1). The BOS+ samples were selected at the time of
the initial diagnosis of BOS as determined by pulmonary function tests. The mean follow-up
post-LTx I BOS+ cohort was 4.1±2.3 years, while that in the BOS− cohort was 3.6±2.7
years. In addition, serum samples from normal individuals (n = 24) were also analyzed for
comparisons. Serum and BAL samples were collected and stored at −70°C until used. All
patients included in the study were negative for antibodies to HLA self-antigens. The
antibodies to HLA were determined using the LABScreen single antigen assay (One
Lambda Inc, CA). Because of fluctuations in mean fluorescence intensity (MFI) between
positive controls, a “positive” DSA was defined to be a ratio of sample to positive-control
MFI of 0.2 or higher [14]. The antibodies to self-antigens (Collagen-V (Col-V) and Kα1
Tubulin (Kα1T)) by enzyme linked immunosorbent assay (ELISA) as detailed earlier [15,
16]. In brief, 1μg/mL of Col-I, Col-V and Kα1T suspended in phosphate-buffered saline
were coated onto an ELISA plate (Col-I and Col-V were obtained from Chemicon/
Millipore, Billerica, MA, and recombinant Kα1T was expressed in our laboratory) and
incubated overnight at 4°C. Diluted patient and normal sera were then added to these plates.
Detection was done using anti-human IgG-HRP (1:10,000), developed using TMB substrate
and read at 450 nm. A sample was considered positive if values were greater than the mean
+ 2 standard deviations (218±31 ng/mL for Kα1T, 125±23 ng/mL for Col-I and 160±28
ng/mL for Col-V) from normal age-matched sera (n=33, age 47.8±12.4, male=19 and
female=14) [17]. Antibody concentration was calculated using a standard curve from known
concentrations of Kα1T, Col-I or Col-V antibodies (Santa Cruz Biotechnology, CA). BOS
was diagnosed according to International Society for Heart and Lung Transplantation
(ISHLT) criteria [18].
2.2 Cell lines
SAEC (American Type Culture Collection, Manassas, VA) were cultured in SAGM (Small
Airway Epithelial Cell Medium, Cambrex BioScience, Charles City, IA). HAEC (Human
Aortic Endothelial Cells, American Type Culture Collection, Manassas, VA) were cultured
in EGM (Endothelial Growth Medium, Cambrex BioScience, Charles City, IA).
2.3 ELISA for HNP(1-3), HBD2 and AAT
HNP1-3 (MyBioSource, Inc., San Diego, CA), HBD2 (Phoenix Pharmaceuticals,
Burlingame, CA) and human AAT (US Biological, Swampscott, MA) quantification ELISA
were performed using kits and the reagents acquired from the respective manufacturer and
according to manufacturer’s instructions.
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2.4 Measurement of HNP- AAT complexes in BAL
BAL was incubated in microtiter wells coated with HNP1-3 antibodies (Abs). HRP-
conjugated AAT Ab was used for detection. Non-complexed HNP in BAL diluted at 1:100
was measured by incubating BAL in microtiter wells coated with AAT Abs. The AAT-HNP
complexes were removed. Unbound complexes were transferred to wells coated with AAT
Abs following which ELISA for free HNPs and AAT were carried out as mentioned earlier.
2.5 Treatment of SAEC or HAEC cells with HNPs
SAEC/HAEC (25×103), serum starved for 16hrs, were cultured with 5, 10 or 20μg/ml of
HNP1 or HNP2 (Bachem, Torrance, CA) with or without equimolar AAT. After 24 hrs,
changes in morphology of the cells were observed. Supernatants from the treated cells were
tested for HBD2 by ELISA. Epithelial or endothelial cells used as controls were also treated
similarly.
2.6 MTT assay
Effect of HNP treatment on viability of epithelial cells was assessed by measuring
mitochondrial activity using MTT (4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium
bromide) assay. After stimulation of SAECs in 96 well plate for 24 hrs with various
concentrations of HNPs (5, 10 or 20 μg/ml) in serum free basal medium, the cells were
incubated with 5mg/ml MTT in PBS for 2 hrs, lysed with DMSO and read at 562 nm.
Viability was calculated as percentage compared to untreated cells.
2.7 Detection of cell surface adhesion molecules (ICAM, VCAM) by Flow cytometry
SAEC (1×106), serum starved for 16hrs, were treated with 1 μg/ml of HNP1 or HNP2
(Bachem, Torrance, CA) for 24 hrs. The cells were collected and tested for the expression of
ICAM and VCAM using FITC-labeled Anti-ICAM or Anti-VCAM Abs (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) by Flow cytometry.
2.8 Cytokine and chemokines quantitation by Luminex assay
Cytokines and chemokines (EGF, GM-CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-8, IL-6,
IL-10, IL-12p40/p70, IL-13, IP-10, KC, MCP-1, MIG, MIP-1α, TNF-α and VEGF) in
supernatants diluted at 1:1000 obtained from cells cultured with HNPs were analyzed using
Luminex Multiplex Bead immunoassays (Invitrogen, Carlsbad, CA) as described by Carson
et.al. previously [19].
2.9 Statistical analysis
Five independent experiments (n=5) were performed and data presented as mean±SEM.
Statistical differences between means were analyzed using a paired or unpaired Student’s t
test, or subjected to analysis of variance and post hoc test. A value of P less than 0.05 was
considered significant.
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3.1 Increased concentration of α-defensins (HNP1-3) and β-defensin (HBD2) in the BAL
and sera of BOS+ LTx recipients following LTx
To determine the expression of defensins in pulmonary inflammation following LTx we
determined the concentration of HNP1-3 in BAL and sera of BOS+ and BOS− LTx
recipients. The sera from age-matched normal individuals were utilized as negative control
cohort. As shown in Figure 1A BAL from BOS+ patients demonstrated significantly higher
levels of HNP1-3 (1066.4 ± 282.9 vs. 532.6 ± 193.7 pg/ml, p=0.03) when compared to BOS
free LTx recipients. The serum HNP1-3 levels were also higher in BOS+ (724.7 ± 129.5 vs.
480 ± 132.1 pg/ml, p=0.04) compared to BOS− LTx recipients and normal sera (268.3 ±
48.2 pg/ml, p=0.009) respectively (Figure 1B). HBD2 concentration was significantly higher
(2.28 fold) (Figure 1C) in BAL samples from BOS+ LTx compared to BOS− LTx patients
(137.7 ± 8.36 vs. 60.45 ± 9.92 pg/ml, p=0.007). Similarly sera from BOS+ LTx
demonstrated elevatedHBD2 concentration (103.2 ± 4.97 pg/ml vs64.0 ± 13.9, p=0.01)
compared to BOS− patients (Figure 1D). In addition the serum concentrations of α-
defensins (p=0.02) and β-defensin (p=0.01) were also significantly elevated in BOS+LTx
recipients compared to normal sera (Figure 1B and 1D). The above findings demonstrate
that following LTx there is a significant increase in the expression of of defensins both in
lungs and systemic circulation of the patients.
3.2 BOS+ LTx recipients demonstrate increased concentrations of AAT-HNP complexes in
BAL along with decreased unbound AAT in circulation
AAT regulates defensins function through formation of complexes [10]. To evaluate the
function of AAT in LTx recipients, we determined the concentrations of AAT-HNP
complexes in BAL and the levels of free unbound AAT in the sera by ELISA. Concentration
of AAT-HNP complexes in BAL samples from BOS+ LTx was 3.6 fold higher (252.4 ±
38.9 vs. 70.8 ± 17.1 pg/ml, p=0.003, n=26, excluding 2 BOS+ patient with AAT deficiency)
compared to BOS-LTx (Figure 2A). Further, the corresponding unbound AAT
concentrations in the sera of BOS+LTx (133.6 ± 25.6 ng/ml) patients demonstrated
markedly less (1.57 fold) concentration compared to BOS− LTx (210.7 ± 54.3 ng/ml,
p=0.05) and normal sera (310.6 ± 28.2 ng/ml, 0.0006) respectively (Figure 2B). Further the
sera concentrations of AAT in BOS− patients were also significantly less (1.47 fold, p=0.03)
compared to normal sera. These results demonstrate that AAT forms complexes with
defensins both in BOS+ and BOS− LTx recipients which can be detected in BAL.
To determine the non-AAT complexed free HNP1-3 in BAL we incubated the BAL samples
thrice (2hr at 37°C) with excess amount of polyclonal AAT Abs to remove AAT-HNP
complexes. After incubations and spinning (10,000 rpm) the unbound supernatant fractions
was tested to confirm complete removal of AAT using ELISA. These AAT depleted BAL
samples were then utilized to measure the concentration of remaining HNP1-3. As shown in
Figure 2C, BAL from BOS+ LTx contained higher HNP1-3 levels than BAL from BOS−
LTx (128.66 ± 23.15 vs. 82.0 ± 14.79 pg/ml, p=0.02) demonstrating that substantial free
HNP1-3 exists in the BAL of BOS+ patients even after forming complex with AAT. We
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propose that the free HNPs may play a role in persistent activation of airway cells following
LTx.
3.3 Treatment of SAEC with increasing concentrations of HNP affects cell viability
Lung epithelium is the immediate target for the host immune response following LTx. To
determine the activation potential of HNPs on airway cells a dose dependent effect of HNP1
or HNP2 treatment on epithelial cell viability was analyzed using MTT assay. Twenty-four
hours treatment with >20 μg/ml of HNP1/HNP2 resulted in cytotoxicity to SAECs reducing
cell survival to less than 76° (Figure 3). However, a physiological concentration, i.e., 1μg/ml
and a 10 fold increased levels did not result in cytotoxicity and the viability remained greater
than 95°.
3.4 HNP activation of SAEC induced expression of inflammatory adhesion molecules and
β-defensins
To evaluate the role of HNPs towards upregulation of inflammatory adhesion molecules, we
incubated SAEC with HNP 1 (0.5μg/ml)/ HNP2 (0.5μg/ml) for 72h and analyzed the
expression of cell surface adhesion molecules, ICAM and VCAM by FACS. To specifically
determine the stimulatory effect of HNP on SAEC, we have preferred to employ purified
HNP instead of BAL from BOS+ or BOS− patients. As demonstrated in Figure 4A and 4B,
expression of both ICAM (12 fold, p=0.004) and VCAM (18 fold, p=0.005) were up-
regulated on SAEC upon HNP1 treatment (Figure 4C). Similar results were also observed
upon treatment with HNP 2 (data not shown).Further, culture supernatants from SAEC
treated with HNP 1 (0.5μg/ml)/HNP2 (0.5μg/ml) with or without AAT for 48 hrs were
analyzed for HBD2 (β-defensins) by ELISA. Results presented in Figure 5 shows significant
increases in HBD2 levels in response to HNP1 or HNP2 treatment (p < 0.001). More
importantly this is inhibited in the presence of AAT. Hence, higher production of α-
defensins by neutrophils can lead to elevated levels of β-defensin inflammatory adhesion
molecule production from the epithelial cells.
3.5 Increase in secretion of cytokines IL-13, IL-8, IL-1β, IL-6 and MCP-1 by SAEC following
addition of HNP1 or HNP2
To determine the role of HNP towards induction of pro-inflammatory cytokines by airway
epithelial cells, culture supernatants from SAEC treated with HNP 1 (0.5μg/ml)/HNP2
(0.5μg/ml), were analyzed for various cytokines by Luminex assay. The effect of AAT on
cytokine production induced by HNP was also determined. Expression and secretion of pro-
inflammatory cytokines (Figure 6A) in the culture supernatant were increased following
incubation with HNP1/2 (IL-13 (9 folds), IL-8 (8 folds), IL-1β (11 folds), IL-6 (5 fold) and
MCP-1 (5 fold) over unstimulated cells. A similar increase was also noted following
incubation with HNP2 (data not shown). These cytokine stimulatory effects of both HNP1/2
were completely abrogated in the presence of AAT. It is also of interest to note that
incubation of SAEC with HNP1/ 2 also resulted in down regulation of anti-inflammatory
cytokine, IL-10 (2 fold, p<0.03). However, AAT reversed the effects of defensins resulting
in significant increase in IL-10 levels (1.7 fold, p=0.002) (Figure 6B).
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3.6 Increased pro-fibrotic growth factor expression by SAEC following stimulation with
HNP1/2
Epithelial proliferation, migration and differentiation are predominantly mediated by growth
factors and their receptors. Hence, culture supernatants from SAEC treated with 1μg/ml
HNP1 or HNP2, with or without AAT for 24 hrs was collected and tested for the presence of
growth factors by Luminex assay. Increased concentration of VEGF (6100 vs 3700 pg/ml,
p<0.05) and EGF (25,500 vs 15,500 pg/ml, p<0.05) following incubation of SAEC with
HNPs are noted which were completely abrogated by AAT (Figure 7). These confirm the
notion that HNPs induce pro-fibrotic growth factors which play a crucial role in the
development of fibrotic changes seen in BOS.
4. Discussion
Long term outcomes following LTx are significantly affected due to development of chronic
rejection (BOS). Several immunological as well as non-immune factors are postulated in its
pathogenesis. Amongst these, increased neutrophil infiltration in the lungs has been shown
to be associated with the development of BOS following LTx [20, 21]. Based on this we
hypothesized that initial inflammatory injury and activation of airway epithelial cells as a
major initiating factor towards development of BOS. Further it has been demonstrated that
direct activation of endothelial cells by antibodies to HLA can induce pro-inflammatory and
pro-fibrotic signaling cascade [22, 23]. To avoid possible co-variate bias, in this study we
selected LTx patients who were negative for donor specific HLA antibodies (DSA) and
auto-antibodies (anti-collagenV and anti-kα1tubulin). Our results clearly demonstrate that
BAL and sera from LTx recipients who developed BOS has increased concentration of
HNP1-3 (α-defensins) (Figure 1). Defensins are small molecular peptides that play an
important role in cellular infiltration and effector functions at the site of infection or injury
[24]. Though defensins have been found to be increased following lung injury, including
transplantation, the mechanisms by which defensins contribute to the development of
chronic rejection remains undefined. We demonstrate that levels of defensins are
significantly elevated in the serum as well as BAL samples of LTx recipients diagnosed with
BOS. Further, we present data that defensins o induce the secretion of cytokines,
chemokines and fibrogenic growth factors by airway epithelial cells which we propose to
play a significant role in the pathogenesis of BOS. A detailed correlative study with respect
to the entire cell profile, microbial analyses, and BOS phenotypes (NRAD, RAS etc) would
be warranted in our future studies.
A complex interaction between innate and adaptive immunity contribute to the propagation
of airway inflammation in BOS. Defensins, a part of the innate immune system [25], are
small molecules released at the site of injury that promotes inflammation and resistance to
infections. They have also been shown to affect immune functions and mediate wound
repair processes [13]. Analysis of the levels of α-defensins and β-defensins in the serum of
LTx recipients with and without BOS (Figure 1) has demonstrated a significant increase in
defensins in BOS+ LTx recipients compared to the BOS− patients. Similarly, defensin levels
in BAL from the LTx recipients were significantly higher in the BOS+ when compared to
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BOS− patients. These results are in agreement with reports of increased levels of defensins
in LTx recipients with BOS [7, 26].
AAT, a serine proteinase inhibitor that forms complexes with α-defensins, can inhibit the
functions of defensins in addition to decreasing its elastase-inhibitory activity [10, 27].
Elastase is vital to phogocytosis of debris in the lungs resulting as by-product of infection or
inhaled pollutants. Following neutrophil elastase activity, AAT inactivates elastase and
prevents further damage to lung tissue. We demonstrate in this report that AAT levels are
lower in patients with increased defensin due to increased complex formation between the
two (Figure 2). These results suggest that measurement of HNP1-3; HBD2 and AAT levels
in the serum of LTx patients may offer a simple, non-invasive diagnostic adjunct for the
diagnosis of chronic lung allograft rejection.
Inflammation and inflammation induced diapedesis in the lungs and airways is regulated
[28] by integrin mediated cell-cell interactions [29] between the epithelial cells. In order to
determine the effect of defensins on epithelial cells, we incubated SAEC with varying
concentrations of defensins and analyzed its effect expression of pro-inflammatory and pro-
fibrotic signaling molecules. Exposure of epithelial cells to defensins as seen in Figure 3,
demonstrated morphological changes and clustering. There was also an increase in adhesion
molecules ICAM and VCAM on the surface of epithelial cells after treatment with HNP1 or
HNP2. Although the secretory inflammatory cytokines are expressed by 24 hrs following
HNP stimulation, the membrane targeting proteins ICAM and VCAM were detected 48 to
72 hrs following the HNP stimulation of SAECs. Exposure of epithelial cells to neutrophil
defensins have been shown to result in chemotaxis of inflammatory cells and proliferation of
epithelial cells and fibroblasts [30]. This may in part be due to the ability of α-defensins to
lyse lung epithelial cells [31] and/or induction of IL-8 production in these cells [20].
Neutrophil defensins have been shown to cause proliferation of epithelial cells, to enhance
lung epithelial airway remodeling and mucin gene expression [32, 33] whereas β-defensins
promote differentiation of keratinocytes [34]. This is in agreement with our hypothesis that
α-defensins can activate SAEC to produce β-defensins which in turn act as chemoattractants
for neutrophils and macrophages, further increasing defensin production (HNP1-3) by the
infiltrating neutrophils as well as HBD2 from the epithelial cells.
The airway remodeling process comprises of epithelial proliferation, migration and
differentiation that are regulated by growth factors and their receptors [35]. Our results
presented in Figure 7A and B also show upregulation of growth factors (VEGF, EGF) on
SAECs in response to α-defensins. Growth factor VEGF has been shown to be involved in
LTx rejection [36]. The VEGF concentration in BAL is particularly decreased at early time
points following LTx, which gradually increase in the absence of rejection or infection.
Further, VEGF becomes lower during active rejection or CMV pneumonia[36]. Increased
VEGF seen in our study (Figure 6A) may contribute towards fibro proliferative changes
seen in BOS following human LTx.
It has been shown that HNPs link innate and adaptive immunity through activation of co-
stimulatory molecules in lung epithelial cells and CD4+ lymphocytes [37]. HBD-1 and
HBD-2 bind to a chemokine receptor CCR-6 [38]. Several studies have shown an important
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contribution for pro-inflammatory cytokines in the development of BOS [39, 40]. HBD-2
bind toll-like receptors (TLR) in the epithelium and activate NFkB pathway and cytokine
gene upregulation. In our study, several cytokines (IL-1β, IL-13, IL-6 and IL-8) and
chemokines (MCP-1) were upregulated upon incubation of SAECs with HNP1 or 2. We also
demonstrate that IL-6 and IL-1β, major pro-inflammatory cytokines, were upregulated upon
stimulation of epithelial cells by HNPs. Chemokine MCP-1 is also produced by epithelial
cells on treatment with HNPs (Figure 6A). This can also increase monocytes infiltration into
the lung leading to inflammation since monocyte-chemotactic activity of defensins has been
reported earlier [41, 42]. We propose that the inflammatory milieu along with epithelial
proliferation and remodeling can expose self antigens including Kα1 Tubulin and Collagen
V to the immune system giving rise to autoimmune responses which are considered to be
important in the pathogenesis of BOS [16, 43].
In conclusion, results presented in this communication demonstrate that α-defensins
produced by neutrophils, infiltrate into the transplanted lung stimulate β-defensin production
by epithelial cells. This leads to increase in cellular activation resulting in increased
production of inflammatory cytokines in the local area. Chronic stimulation of epithelial
cells by the resulting defensins can also result in increased expression of cell adhesion
molecules, pro-inflammatory cytokines, and pro-fibrotic growth factor production resulting
in epithelial cell proliferation and remodeling that contribute towards the development of
BOS. We propose that the growth factors produced not only by epithelial cells but also
endothelial cells upon chronic stimulation by defensins can lead to the fibrotic changes seen
in BOS. Therefore, defensins interactions with epithelial and endothelial cells of the
transplanted lung serves as a primary link between the innate and adaptive immunity
following human LTx and play an important role in the pathogenesis of BOS.
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BOS bronchiolitis obliterans syndrome
Col-V Collagen-V
DSA donor specific antibodies
ELISA enzyme-linked immunosorbent assay
EGF epidermal growth factor
HAEC human aortic endothelial cells
HBD2 human β-defensin2
HNP human neutrophil peptide
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ICAM intercellular adhesion molecule
Kα1T Kα1 Tubulin
LTx lung transplantation
MFI mean fluorescence intensity
MCP-1 monocyte chemotactic protein-1
SAEC small airway epithelial cells
VCAM vascular cell adhesion molecule
VEGF vascular endothelial growth factor
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Figure 1. HNP (1-3) in the BAL fluid (A) and serum (B) of BOS+ LTx recipients are higher than BOS− recipients
HNP (1-3) levels were measured in the BAL fluid and serum (normal control, n= 24) of BOS+ (n= 28) and BOS− (n= 26) by
ELISA.
Human β-defensin (HBD2) in the BAL fluid (C) and serum (D) of BOS+ LTx recipients are higher than BOS− recipients.
HBD2 levels were measured in the BAL fluid and serum (normal control, n= 24) of BOS+ (n= 28) and BOS− (n= 26) by
ELISA.
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Figure 2. High concentrations of HNP-AAT complexes are found in BAL fluid from BOS+ than BOS− patients
BAL samples from BOS+ (n= 26, excluding 2 BOS+ patient with AAT deficiency) patients were compared to BOS− (n= 26)
patients for HNP-AAT complex by ELISA (A). AAT levels in the serum samples from the above BOS+ and BOS− patients and
normal sera (n= 24) were also analyzed for the presence of non-complexed AAT and HNP (n=10) using ELISA (B and C).
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Figure 3. SAEC treatment with HNPs leads to cell death
SAEC grown in 24 well plates were treated with 1, 10 and 20 μg/ml HNP1 or HNP2 respectively for MTT assay. Five
independent experiments (n=5) were performed and data presented as mean±SEM; significance (p<0.05) was determined by
student t-test.
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Figure 4. Treatment of SAEC with HNP1 or HNP2 results in ICAM and VCAM expression
ICAM and VCAM were analyzed on the surface of SAEC treated with HNP1 (0.5 μg/ml) and HNP2 (0.5μg/ml) by using FITC
conjugated Anti-ICAM (A) and Anti-VCAM (B) Abs in Flow cytometric detection and the fold increase in expression is
represented in figure 4C. (A-B) light color represented unstimulated cells and dark color represented HNP stimulated SAECs.
Five independent experiments (n=5) were performed and data presented as mean±SEM; significance (p<0.05) was determined
by student t-test.
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Figure 5. Treatment of SAEC with HNP1 or 2 results in more HBD2 production from the cells, which is inhibited in the presence of
AAT
SAEC grown in 6 well plates were treated with HNP1 or HNP2 with or without equimolar AAT as mentioned in methods for 24
hrs. HBD2 production was measured by ELISA in the culture supernatant. Five independent experiments (n=5) were performed
and data presented as mean±SEM; significance (p<0.05) was determined by student t-test.
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Figure 6. (A) Treatment of SAEC with HNP1 results in production of cytokines, which is inhibited in the presence of AAT
SAEC grown in 6 well plates were treated with 1μg/ml HNP1 with or without equimolar AAT as mentioned in methods for 24
hrs. Cytokines production was measured by Luminex method in the culture supernatant. (B) Treatment of SAEC with HNP1 or
2 results in less IL-10 production from the cells. SAEC grown in 6 well plates were treated with 10μg/ml HNP1 or HNP2 as
mentioned in methods for 24 hrs. IL-10 production was measured by Luminex method in the culture supernatant. Five
independent experiments (n=5) were performed and data presented as mean±SEM; significance (p<0.05) was determined by
student t-test.
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Figure 7. Growth factors are produced in response to HNP treatment. (A) Treatment of SAEC with HNP1 or HNP2 results in VEGF
production from the cells, which is inhibited in the presence of AAT
SAEC grown in 6 well plates were treated with 10μg/ml HNP1 or HNP2 with or without equimolar AAT as mentioned in
methods for 24 hrs. Growth factor production was measured by Luminex method in the culture supernatant. (B) Treatment of
HAEC with HNP1 or 2 results in EGF production from the cells, which is inhibited in the presence of AAT. HAEC grown in 6
well plates were cultured with 10μg/ml HNP1 or HNP2 with or without equimolar AAT as mentioned in methods for 24 hrs.
Growth factor production was measured by Luminex method in the culture supernatant. Five independent experiments (n=5)
were performed and data presented as mean±SEM; significance (p<0.05) was determined by student t-test.
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Table 1
Clinical and demographic characteristics of lung transplant patients
Clinical and demographic characteristics BOS+ (n =28) BOS− (n =26)
Age (years)




















Chronic obstructive pulmonary disease
Primary pulmonary hypertension
Interstitial pulmonary fibrosis
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